Showing results (21-30 of 4,830) with videos related to
Sort By:
Pageof 483
Clinics in Liver Disease|July 11, 2017
Treatment of Extrahepatic Manifestations of Hepatitis C VirusElisabetta Degasperi, Alessio Aghemo, Massimo ColomboJournal of the International AIDS Society|April 11, 2018
What do clinicians need to watch for with direct-acting antiviral therapy?Alessio Aghemo, Lionel Piroth, Sanjay BhaganiExpert Opinion on Pharmacotherapy|November 10, 2015
Daclatasvir for the treatment of chronic hepatitis CElisabetta Degasperi, Alessio Aghemo, Massimo ColomboAntiviral Therapy|February 14, 2014
Interleukin 28B genotype and insulin resistance in chronic hepatitis C patientsElisabetta Degasperi, Luca Valenti, Alessio Aghemo, et al.Expert Review of Anti-Infective Therapy|October 7, 2009
Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis CAlessio Aghemo, Maria Grazia Rumi, Massimo ColomboLiver International : Official Journal of the International Association for the Study of the Liver|January 24, 2021
Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirementsLoreta A Kondili, Antonio Craxì, Alessio AghemoDigestive Diseases (Basel, Switzerland)|June 26, 2013
The size of the problem: clinical algorithmsAlejandro Forner, Jordi BruixWorld Journal of Gastroenterology|March 30, 2013
Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategiesCristina Della Corte, Alessio Aghemo, Massimo ColomboAnnali Dell'Istituto Superiore Di Sanita|September 23, 2021
Challenges on the achievement of World Health Organization goals for HCV elimination in Italy: need for a Regional programmatic approach on screening and linkage to care. CommentaryLoreta A Kondili, Alessio Aghemo, Massimo AndreoniNature Reviews. Gastroenterology & Hepatology|July 21, 2010
Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis CAlessio Aghemo, Maria Grazia Rumi, Massimo ColomboPageof 483